A new molecular test from bioTheranostics—the Prostate Cancer Index—is a
strong predictor of prostate cancer recurrence and may improve upon the
current standard of care for assessing risk ... read more
bioTheranostics’
CancerTYPE®
ID molecular cancer classifier demonstrated superior accuracy
compared with immunohistochemistry (IHC) in identifying the primary site
... read more
A major head-to-head study comparing bioTheranostics’
Breast
Cancer Indexsm (BCI) to the Oncotype Dx Breast Cancer
Assay and IHC4 for breast cancer ... read more